Ryvu Therapeutics SA · GPW:RVU
Ryvu Therapeutics SA — Investor Presentation (November 2026)
41 slides from Ryvu Therapeutics SA's investor presentation, November 2026
Slide 1: Corporate Presentation
Developing therapeutics at the forefront of oncology Corporate Presentation November 2026
Slide 2: Note on the presentation and forward-looking statements
Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submi
Slide 3: Accelerating oncology innovation
First-in-class CDK8/19i romaciclib demonstrated efficacy in post-VEN AML – high unmet need; expansion data generating in 2026 to support accelerated development Accelerating oncology First-in-class pipeline supports long-term innovation: innovation precision oncology and novel ADC payloads to patien
Slide 4: Broad pipeline addressing emerging targets in oncology
Broad pipeline addressing emerging targets in oncology PRECLINICAL AND CLINICAL PROGRAMS PARTNER / EXPECTED PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE I PHASE II COLLABORATION MILESTONES R/R AML Ph. II data (combo with venetoclax) RIVER-81 at ASH 2026 Romaciclib (RVU120) (CDK8/19) Children's Mem
Slide 5: Team with a strong track record of clinical development
Team with a strong track record of clinical SUPERVISORY BOARD development and shareholder value creation Piotr Romanowski, M.D. Ph.D., Chairman Tadeusz Wesołowski, Ph.D, Deputy Chairman Scott Z. Fields, M.D. Peter Smith, Ph.D Rafał Chwast, MSc Paweł Przewięźlikowski, MSc, MBA Krzysztof Brzózka, Ph
Slide 6: Romaciclib (RVU120): First-in-Class CDK8/19 Inhibitor
Romaciclib (RVU120): First-in-Class CDK8/19 Inhibitor
Slide 7: Romaciclib: clinical-stage, first-in-class CDK8/19 kinase inhibitor
Romaciclib (RVU120): clinical-stage, first-in-class, small molecule Romaciclib CDK8/19 kinase inhibitor developed and fully-owned by Ryvu Romaciclib uniquely targets transcriptional factors Addressing high unmet need with significant clinical and commercial potential to disrupt oncogenic pathways Ac
Slide 8: Romaciclib clinical Studies
Romaciclib Development priority is to confirm activity in R/R AML 2025 2026 2027 2028 2029 2030 I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV RIVER-81: AML: R/R AML post-VEN (RVU120+VEN) Dose expansion Confirmatory part Romaciclib clinical Studies Exploratory part 1L AML, u
Slide 9: Romaciclib has the potential to overcome VEN resistance
Romaciclib has the potential to overcome VEN resistance AML and improve combination efficacy Mechanism of romaciclib & VEN synergy in AML Romaciclib with VEN in AML Resistance to VEN poses a significant clinical challenge: ~80% of patients are not eligible for effective subsequent therapy Romaciclib
Slide 10: RIVER-81: Phase II study of romaciclib with venetoclax
RIVER-81: Phase II study of romaciclib in combination AML with venetoclax in VEN-refractory AML patients – dose expansion A multicenter, open-label clinical trial (RIVER-81, NCT06191263) EXPLORATORY PART 1 EXPANSION PART 2 CONFIRMATORY PART 3 Dose finding Dose-expansion Simon's 2-stage Confirmatory
Slide 11: Romaciclib induced CR/CRi in patients who failed venetoclax
AML Romaciclib induced CR/CRi in patients who failed venetoclax Dose finding: Dose-expansion: Dose finding: Dose finding: Dose finding: Cohorts 1- 3 Stage 1 Cohort 4 Cohort 6a Cohort 6b Treatment schedule RVU120 125 – 250 mg RVU120 250 mg QOD RVU120 150 mg QD RVU120 200 mg QD RVU120 250 mg QD QOD +
Slide 12: Favorable safety profile in RIVER-81 and previous studies
Favorable safety profile in RIVER-81 and previous studies AML with limited cytopenias TEAEs regardless of causality occurring in ≥10% of patients Romaciclib in combination with VEN is safe and tolerated in patients with VEN-failed AML AEs All grades Grade 1 & 2 Grade 3 Grade 4 Grade 5 Nausea 34 (58
Slide 13: Romaciclib in AML – Dose expansion initiated
Romaciclib in AML – Dose expansion initiated AML At 150 mg QD, a CR rate of 29% (2/7) Current status: data to be confirmed 01 04 with a median DoR of 156 days has been achieved in the RIVER-81 dose expansion (n ≈ 30 patients); Safety and tolerability of romaciclib No relevant aggravation 02 05 of VE
Slide 14: Romaciclib in myelofibrosis: clinical benefit in exploratory study
Romaciclib in myelofibrosis: clinical benefit in exploratory study MF Opportunity in myelofibrosis Romaciclib in myelofibrosis • Growing market with many patients undiagnosed or not treated • Disrupts downstream signaling events, mitigating MF symptoms • Long durations of therapy • Reduces splenomeg
Slide 15: Data in patients with myelofibrosis confirm romaciclib as clinically active
MF Data in patients with myelofibrosis confirm romaciclib as a clinically active drug Safety profile of romaciclib as a single agent Significant and durable improvements 01 and in combination with RUX confirmed; 03 of myelofibrosis-associated symptoms cytopenia-sparing profile confirmed, were observ
Slide 16: High unmet need and market potential in AML and MF
High unmet need and market potential in AML and MF Romaciclib AML (Acute Myeloid Leukemia) • The most common, highly aggressive type of acute leukemia occurring in adults(1) Global AML Market (4) • Annual incidence in the US at ~20,800 with an est. 11,220 deaths in the US in 2024(2) USD 6.6B • SoC a
Slide 17: Phase I study of romaciclib with everolimus in medulloblastoma
Phase I study of romaciclib in combination with everolimus Medulloblastoma in children with recurrent or progressive Group 3 or 4 medulloblastoma Treatment with RVU120 alone or in combination with mTOR Pediatric medulloblastoma: the most common embryonal CNS tumor inhibition suppresses MB orthotopic
Slide 18: Romaciclib is a first-in-class CDK8/19 inhibitor accelerating to potential approval
Romaciclib is a first-in-class CDK8/19 inhibitor Romaciclib accelerating to potential approval Efficacy and safety data in AML and MF AML: efficacy demonstrated clinically in a post-VEN population with no effective options support accelerated development MF: efficacy post-JAK with disease-modifying
Slide 19: RVU305: MTA-cooperative PRMT5 inhibitor
RVU305: MTA-cooperative PRMT5 inhibitor • Built for RAS combinations in MTAP-deleted cancers • Brain-penetrant; IND/CTA-ready
Slide 20: RVU305: a clinic-ready PRMT5 inhibitor built for RAS combinations
RVU305: a clinic-ready PRMT5 inhibitor built for RAS combinations and designed around the class's safety limits Mechanism & • MTA-cooperative PRMT5 inhibitor: hits MTAP-deleted tumor cells while sparing normal cells Patients • MTAP is deleted in 7–15% of cancers – most often in glioblastoma, mesothe
Slide 21: RAS + PRMT5 inhibition in MTAP-deleted pancreatic cancer is clinically validated
RAS + PRMT5 inhibition in MTAP-deleted pancreatic cancer is clinically validated Adding a PRMT5 inhibitor to a RAS(ON) inhibitor gave deep responses with both a multi-selective and a G12D-selective agent RAS inhibitors combined with a PRMT5 inhibitor in the clinic 82% RAS inhibitor (company) PRMT5 i
Slide 22: RVU305: differentiated on efficacy, RAS combinations, safety and speed
RVU305: differentiated on efficacy, RAS combinations, safety and speed to the clinic Best-in-class potential built on four reinforcing axes EFFICACY RAS COMBINATIONS SAFETY SPEED TO THE CLINIC • Deeper, durable responses: • Class clinically validated: • Preserved hematopoiesis: • Clinic-ready: 10/10
Slide 23: RVU305 achieves 10/10 complete responses in MTAP-deleted DLBCL
RVU305 achieves 10/10 complete responses and durable tumor control in MTAP-deleted DLBCL, favorable vs. BMS-986504 Strong antitumor efficacy 10/10 complete responses demonstrated in vivo at 75 mg/kg BID dose, in DoHH2 MTAP-deleted model (DLBCL) favorable vs. BMS-986504 Individual tumor volume Indivi
Slide 24: RVU305 is brain-penetrant and induces tumor regression in glioblastoma model
RVU305 is brain-penetrant and induces tumor regression in an orthotopic MTAP-deleted glioblastoma model Intracranial U87-LUC GBM model Free brain concentrations exceed pharmacologically relevant thresholds 100 0.1, 0.2,63.977435 62.188789 12.1, 12.2,63.977435 62.188789 0.3, 0.4,60.450124 58.760068 1
Slide 25: RVU305 preserves hematopoietic function and synergizes with a RAS(ON) inhibitor
RVU305 preserves hematopoietic function and synergizes with a RAS(ON) inhibitor in KRAS-mutant MTAP-deleted models Safety of RVU305 was evaluated in 7-day erythroid Pancreatic cell line models Lung cell line models and myeloid cell HemaToxTM viability assay (MTAPdel; KRASmut) (MTAPdel; KRASmut) M TA
Slide 26: Ryvu Discovery Engine
Ryvu Discovery Engine • ONCO Prime • Novel ADC Payloads
Slide 27: Ryvu's discovery engine: Dual-pronged strategy
Ryvu’s discovery engine: Dual-pronged strategy with potential to generate multiple oncology medicines Novel precision oncology Next-generation ONCO Prime ADCs drug discovery platform novel ADC payloads Broad potential to discover novel precision oncology targets, Potential to improve efficacy, safet
Slide 28: Driving precision oncology discovery with ONCO Prime platform
Driving novel precision oncology drug discovery and development ONCO Prime with Ryvu’s ONCO Prime platform Discovering Novel Precision Oncology Targets, Ryvu’s CRISPR-based target Discovery Platform including Synthetic Lethal Targets Engineered Model Patient-Derived Cells (PDCs) Synthetic Common APC
Slide 29: Initial ONCO Prime data presented in CRC
Initial ONCO Prime data presented in CRC; ONCO Prime broad applicability across oncology • Third most prevalent cancer worldwide • Estimated number of colorectal cancers in the US for 2024 are 153,000 new cases1 CRC • Diagnosed usually at an advanced stage. Mortality still remains high. Five-year su
Slide 30: ONCO Prime is accelerating development of novel precision medicine targets
ONCO Prime is accelerating the development ONCO Prime of novel precision medicine targets, including synthetic lethal targets Modeling cancer progression High Throughput Screenings Novel Targets & Treatments APC KRAS TP53 SMAD4 Patient-derived material Ryvu’s OncoPrime platform has broad potential t
Slide 31: RVU602 – addressing limitations of TOP1- and tubulin-targeting payloads
ADC Payloads RVU602 – addressing limitations of TOP1- and tubulin-targeting payloads The crowded default choices Shared failure mode RVU602 answer TOP1 Cross-resistance Orthogonal MoA DXd / SN-38 Tumors progressing on one TOP1i-ADC Targets essential protein RVUX1; no TOP1 or DNA damage resist the ne
Slide 32: RVU602 compounds show low-nanomolar potency across 272 cell lines
RVU602 next generation compounds show low-nanomolar potency ADC Payloads across a 272-cell-line panel spanning multiple cancer indications Median: RVU602 Series 3 DXd IC50 [nM] 6.0 2.8 GI50 [nM] 5.7 3.0 LC50 [nM] 14 >100 Max. effect high moderate–high GI50 = 30 nM; 90% of cell lines GI50 = 10 nM; 67
Slide 33: RVU602 based ADCs shows excellent efficacy and tolerability in vivo
ADC Payloads RVU602 based ADCs shows excellent efficacy and tolerability in vivo In vitro potency In vivo Target engagement In vivo efficacy RVU602 ADC with a Series 3 payload, dosed at 5 mg/kg BIW, is efficacious and well tolerated. No tumor regrowth was observed over 6 weeks after the last dose. S
Slide 34: STING activating Antibody-Drug Conjugates
ADC Payloads STING activating Antibody-Drug Conjugates STING activating Antibody-Drug Conjugates • Proprietary STING agonist chemotype • ADC development expertise • Localized immune response • Small-molecule, non-CDN structures • Antibodies against cancer-relevant after systemic administration antig
Slide 35: Collaborations and Corporate Progress
Collaborations and Corporate Progress
Slide 36: Dapolsertib collaboration with Menarini
Dapolsertib (PIM/FLT3 inhibitor) collaboration with Menarini Dapolsertib (MEN1703) JASPIS-01 Phase II clinical study in R/R Aggressive B-cell NHL and SPHENE-01 in MF MANAGEABLE SAFETY AND ENCOURAGING CLINICAL PARTNERSHIP AGREEMENT WITH MENARINI ACTIVITY R/R Aggressive B-cell NHL GROUP JASPIS-01 JASP
Slide 37: Keelira adds a complementary growth platform
Keelira adds a complementary growth platform while protecting Ryvu’s pipeline WITHIN RYVU THERAPEUTICS DISTINCT PROGRAM GOVERNANCE Ryvu proprietary programs Keelira client programs Ryvu’s oncology pipeline, External client programs are delivered governed and prioritized under a dedicated QMS, separa
Slide 38: Financial Results: H1 YTD 2026
Financial Results: H1 YTD 2026 H1 YTD H1 YTD € million 20251 20251 20261 Cash position as of September 10, 2026 Revenues 20.7 10.0 9.1 Partnering 14.7 6.9 6.8 €14.4M (PLN 62.1M)4 Grants 6.0 3.1 2.3 In addition, as of September 23, the company Total Costs2 43.0 22.6 15.9 has secured approximately €42
Slide 39: Ryvu's Vision: key goals and business pipeline
Ryvu’s Vision: Ryvu will improve the lives of cancer patients worldwide 2026 / KEY GOALS ROMACICLIB PROGRESS SUMMARY • Romaciclib AML development (incl. potential fast-to-market strategy) • Encouraging efficacy demonstrated in AML and MF RIVER-81 Phase II study dose expansion (N=30) initiated • AML
Slide 40: Ryvu equity summary
Ryvu equity summary Top Holders3 1 Paweł Przewięźlikowski (through Benevora Family Foundation) 17.2% IPO on the WSE Nov 2014, Oct 2019 2 OFE Allianz Polska 9.9% Corporate Split: Selvita and Ryvu 3 BioNTech SE 8.3% Ticker: WSE RVU 4 OFE Nationale Nederlanden 6.0% 5 Tadeusz Wesolowski with Wesolowski
Slide 41: Thank you
Thank you CONTACT: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com ir@ryvu.com
Ryvu Therapeutics — Investor Presentation (November 2026) on 6ix